Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
Overview
flowchart TD
Cryptic_Hdgfl2["Cryptic Hdgfl2"] -->|"expressed in"| Blood["Blood"]
HSPA1A["HSPA1A"] -->|"expressed in"| blood["blood"]
HSPA1B["HSPA1B"] -->|"expressed in"| blood["blood"]
style blood fill:#4fc3f7,stroke:#333,color:#000
This clinical trial investigates the effects of blood flow restriction (BFR) combined with instability resistance training (IRT) on balance, mobility, and motor function in patients with Parkinson's disease (PD). The study aims to determine whether low-intensity resistance exercises with BFR are well-tolerated and effective for improving muscle strength, balance, and physical function in individuals with PD.
Blood flow restriction training involves applying a pneumatic cuff to the proximal thighs during exercise, partially restricting arterial inflow while completely occluding venous outflow. This technique allows for muscle strength gains at significantly lower loads (20-30% of 1RM) compared to traditional resistance training, making it particularly suitable for patients who cannot tolerate high-intensity exercise.
Trial Details
...Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
Overview
Mermaid diagram (expand to render)
This clinical trial investigates the effects of blood flow restriction (BFR) combined with instability resistance training (IRT) on balance, mobility, and motor function in patients with Parkinson's disease (PD). The study aims to determine whether low-intensity resistance exercises with BFR are well-tolerated and effective for improving muscle strength, balance, and physical function in individuals with PD.
Blood flow restriction training involves applying a pneumatic cuff to the proximal thighs during exercise, partially restricting arterial inflow while completely occluding venous outflow. This technique allows for muscle strength gains at significantly lower loads (20-30% of 1RM) compared to traditional resistance training, making it particularly suitable for patients who cannot tolerate high-intensity exercise.
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06508801 |
| Status | Recruiting |
| Phase | Not Applicable (Feasibility) |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Principal Investigator | Anjali Sivaramakrishnan, PhD, PT |
| Collaborators | National Institute on Aging (NIA) |
| Intervention | Blood Flow Restriction + Instability Resistance Training |
| Enrollment | 20 participants (estimated) |
| Start Date | January 7, 2025 |
| Primary Completion | December 2026 |
| Completion Date | December 2026 |
| Location | San Antonio, Texas, United States |
Study Design
Rationale
Parkinson's disease is a progressive neurodegenerative disorder affecting the dopaminergic neurons in the substantia nigra pars compacta. Motor symptoms include tremor, rigidity, bradykinesia, and postural instability. Postural instability is particularly disabling as it leads to falls, reduced mobility, and decreased quality of life.
Traditional high-intensity resistance training can be challenging for PD patients due to:
- Reduced exercise tolerance
- Fatigue during extended exercise sessions
- Risk of orthostatic hypotension
- Balance deficits that make heavy lifting unsafe
Blood flow restriction training offers a solution by:
- Inducing muscle hypertrophy and strength gains at low loads
- Activating fast-twitch muscle fibers normally recruited only at high loads
- Stimulating hormonal and metabolic responses comparable to high-intensity exercise
- Reducing the mechanical stress on joints and supporting structures
Intervention Protocol
BFR plus IRT Group:
- Blood flow restriction training combined with instability resistance training
- 2 sessions per week for 6 weeks
- BFR at 20-30% of 10 repetition maximum (10RM)
- Exercises: toe raises, lunges, single leg stance on unstable surfaces
IRT Only Control Group:
- Instability resistance training without blood flow restriction
- 2 sessions per week for 6 weeks
- Same exercises on unstable surfaces
Unstable Training Devices
The trial utilizes progressive instability devices:
Foam pad
Dyna disc
Balance disc
BOSU-ball®Progression occurs as participants demonstrate reduced body sway on each device.
Mechanism of Action
Blood Flow Restriction Physiology
Blood flow restriction works through several mechanisms:
Metabolic Stress: Partial occlusion creates a hypoxic environment that accumulates metabolites (lactate, inorganic phosphate) in the muscle, stimulating muscle growth pathways.
Hormonal Response: BFR exercise increases secretion of growth hormone and IGF-1, promoting muscle protein synthesis.
Muscle Fiber Recruitment: The technique preferentially activates fast-twitch (Type II) muscle fibers, which are critical for strength but typically require high loads to engage.
Cellular swelling: The accumulation of metabolites and fluid within muscle cells activates anabolic signaling pathways.
Autoregulation: BFR may improve proprioception and neuromuscular control, potentially benefiting balance in PD patients.Instability Training Benefits
Instability resistance training targets:
- Postural control and equilibrium
- Core stability
- Proprioceptive feedback
- Adaptive muscle activation patterns
- Balance reactions and compensatory strategies
Outcome Measures
Primary Outcomes
| Measure | Description |
|---------|-------------|
| Feasibility Metric | Dropout and adverse event rate <20% (acceptable if ≤2/10 participants) |
Secondary Outcomes
| Measure | Timepoint | Description |
|---------|-----------|-------------|
| miniBESTest | Baseline to 14 weeks | Balance evaluation (0-28 points, 14 items scored 0-2) |
| 30-second Chair Stand | Baseline to 14 weeks | Functional mobility - stands from sitting in 30 seconds |
| MDS-UPDRS Part III | Baseline to 14 weeks | Motor severity (0-72 points, 18 items) |
| Postural Sway (BioSway) | Baseline to 14 weeks | Postural stability on Biodex BioSway |
| Spinal Excitability | Baseline to 14 weeks | H-reflex recruitment curves |
| Hip Abductor Strength | Baseline to 14 weeks | Isokinetic dynamometry |
| Knee Extensor Strength | Baseline to 14 weeks | Isokinetic dynamometry |
| Ankle Plantar Flexor Strength | Baseline to 14 weeks | Isokinetic dynamometry |
| PDQ-39 | Baseline to 14 weeks | Quality of life (0-100, lower = better) |
Eligibility Criteria
Inclusion Criteria
Males and females aged 40-85 years
Diagnosis of idiopathic Parkinson's disease (UK Brain Bank criteria)
Hoehn and Yahr stage 2-4
Mini-Mental Scale Examination score ≥23Exclusion Criteria
Cardiovascular disease, uncontrolled hypertension (≥140/90 mmHg), orthostatic hypotension
Deep vein thrombosis, varicose veins, rhabdomyolysis history
Ankle-brachial index ≤0.9 or >1.3
Neurological disorders: stroke, multiple sclerosis, tumors, ALS
Muscle disease: muscular dystrophy, myopathy
Uncontrolled diabetes, severe osteoporosis, cognitive impairment
BMI >40
Absolute contraindications to exercise (per ACSM)
Lower extremity surgery within past 6 months
Pre-menopausal not on birth control, pregnant, or planning pregnancyScientific Rationale
Parkinson's Disease and Postural Instability
Postural instability in PD results from:
- Degeneration of dopaminergic neurons in the substantia nigra
- Dysfunction of the basal ganglia-thalamocortical circuits
- Impaired integration of sensory information for balance
- Reduced automaticity of postural responses
The combination of BFR and instability training may address multiple aspects:
- BFR improves muscle strength, which supports postural control
- Instability training specifically targets balance mechanisms
- Low-intensity approach is safer for fall-prone patients
- Both interventions are time-efficient (45-minute sessions)
Spinal Excitability Assessment
The trial includes peripheral nerve stimulation to measure spinal excitability via H-reflex. This addresses whether BFR affects the monosynaptic reflex arc, which is relevant because:
- H-reflex is modulated by descending dopaminergic pathways
- PD patients may show altered H-reflex characteristics
- Changes could indicate disease modification beyond strength gains
References
[Sivaramakrishnan et al., Blood Flow Restriction for Optimizing Balance in Parkinson's Disease (2025)](https://clinicaltrials.gov/study/NCT06508801)
[UK Parkinson's Disease Society Brain Bank diagnostic criteria (2003)](https://pubmed.ncbi.nlm.nih.gov/15073256/)
[The mini-BESTest: A comprehensive balance test for older adults - J Geriatr Phys Ther](https://pubmed.ncbi.nlm.nih.gov/21965156/)
[PDQ-39: Development and validation - J Neurol Neurosurg Psychiatry](https://pubmed.ncbi.nlm.nih.gov/10874065/)
[Blood Flow Restriction Exercise: Safety Considerations - J Funct Morphol Kinesiol](https://doi.org/10.3390/jfmk6030153)
[Physiological mechanisms of BFR exercise - J Sport Health Sci](https://doi.org/10.1016/j.jshs.2020.04.004)Related Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Transcranial Direct Current Stimulation for PD Gait](/clinical-trials/tdcs-pd-gait-nct06324448)
- [tDCS for Motor Function in PSP](/clinical-trials/tdcs-motor-function-psp-nct07291687)
- [Physical Therapy Modalities](/rehabilitation/physical-therapy-parkinsons)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
- [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
- [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT
- [Circadian-Synchronized LRP1 Pathway Activation](/hypothesis/h-7e0b5ade) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: LRP1, MTNR1A, MTNR1B
- [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
- [Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFR1
- [Piezoelectric Nanochannel BBB Disruption](/hypothesis/h-7a8d7379) — <span style="color:#ff8a65;font-weight:600">0.40</span> · Target: CLDN5, OCLN
Related Analyses:
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄